Raymond James Financial Inc. acquired a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 189,364 shares of the specialty pharmaceutical company's stock, valued at approximately $6,847,000. Raymond James Financial Inc. owned 0.34% of Supernus Pharmaceuticals as of its most recent SEC filing.
Other institutional investors have also recently made changes to their positions in the company. Bank of Montreal Can boosted its stake in Supernus Pharmaceuticals by 6.6% in the 4th quarter. Bank of Montreal Can now owns 7,595 shares of the specialty pharmaceutical company's stock worth $275,000 after purchasing an additional 473 shares during the period. Exchange Traded Concepts LLC increased its holdings in Supernus Pharmaceuticals by 2.6% in the 4th quarter. Exchange Traded Concepts LLC now owns 22,119 shares of the specialty pharmaceutical company's stock valued at $800,000 after acquiring an additional 560 shares during the last quarter. HighTower Advisors LLC lifted its stake in Supernus Pharmaceuticals by 7.3% in the 4th quarter. HighTower Advisors LLC now owns 9,130 shares of the specialty pharmaceutical company's stock worth $330,000 after purchasing an additional 624 shares in the last quarter. Bridge City Capital LLC boosted its holdings in shares of Supernus Pharmaceuticals by 0.8% during the 4th quarter. Bridge City Capital LLC now owns 94,997 shares of the specialty pharmaceutical company's stock valued at $3,435,000 after purchasing an additional 761 shares during the last quarter. Finally, Rhumbline Advisers increased its holdings in shares of Supernus Pharmaceuticals by 0.5% in the fourth quarter. Rhumbline Advisers now owns 172,444 shares of the specialty pharmaceutical company's stock worth $6,236,000 after purchasing an additional 800 shares during the last quarter.
Supernus Pharmaceuticals Stock Up 2.8 %
Supernus Pharmaceuticals stock traded up $0.87 during midday trading on Friday, reaching $32.22. The stock had a trading volume of 356,067 shares, compared to its average volume of 496,014. Supernus Pharmaceuticals, Inc. has a 52-week low of $25.53 and a 52-week high of $40.28. The company has a fifty day moving average of $31.94 and a 200 day moving average of $34.99. The firm has a market cap of $1.80 billion, a price-to-earnings ratio of 30.11 and a beta of 0.90.
Analyst Ratings Changes
SUPN has been the subject of several research analyst reports. StockNews.com upgraded Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Thursday, April 17th. Cantor Fitzgerald restated a "neutral" rating and issued a $36.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.
Read Our Latest Research Report on Supernus Pharmaceuticals
Insider Transactions at Supernus Pharmaceuticals
In related news, SVP Jonathan Rubin sold 927 shares of the business's stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the sale, the senior vice president now owns 7,853 shares in the company, valued at approximately $307,444.95. The trade was a 10.56 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Padmanabh P. Bhatt sold 700 shares of the company's stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $39.62, for a total transaction of $27,734.00. Following the completion of the sale, the vice president now directly owns 10,149 shares of the company's stock, valued at approximately $402,103.38. This trade represents a 6.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 11,104 shares of company stock worth $440,263. 9.30% of the stock is currently owned by company insiders.
Supernus Pharmaceuticals Profile
(
Free Report)
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.
See Also
Before you consider Supernus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Supernus Pharmaceuticals wasn't on the list.
While Supernus Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
